Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Verona Pharma
Verona Pharma
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Verona Pharma gets new CEO and COO
Respiratory-focused biopharma has appointed David Zaccardelli as President and CEO, and Mark Hahn as COO
Verona Pharma makes two senior appointments
Nina Church joins as Executive Director of Global Clinical Development and Nancy Herje as Senior Director of Clinical Operations
Regulatory
Verona gets EU patent for ensifentrine formulation extended to 2035
Drug by the British company is in Phase 2b clinical trials for chronic obstructive pulmonary disease
Recruitment
Verona Pharma announces departure of Chief Medical Officer
Pharmaceutical
Verona Pharma appoints Vice President of Regulatory Affairs
Regulatory
Pharmacokinetic clinical study initiated by Verona Pharma
Verona Pharma initiates US clinical pharmacokinetic study for RPL554 following acceptance of an investigational new drug (IND) application by the US Food and Drug Administration (FDA)
Quintiles outsource Verona COPD and cystic fibrosis therapeutics
Verona Pharma enters global strategic clinical development services agreement with QuintilesIMS for RPL554
Subscribe now